Ethylparaben

Ethylparaben

SCHEMBL5311680

CCOC(=O)c1ccc(O)cc1.CCOC(=O)c1ccc(O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 1.00
CA1 P00915 6/20 1.00
CA2 P00918 6/20 1.00
CA7 P43166 6/20 1.00
CA9 Q16790 6/20 1.00
CA14 Q9ULX7 6/20 1.00
ESR1 P03372 3/20 1.00
ESR2 Q92731 1/20 1.00
TSHR P16473 2/20 0.71
ALDH1A1 P00352 2/20 0.71
CHRM1 P11229 1/20 0.71
SLC6A2 P23975 1/20 0.71
KDR P35968 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
LMNA P02545 3/20 0.68
CYP1A2 P05177 2/20 0.68
CYP3A4 P08684 1/20 0.68
MAOA P21397 1/20 0.68
MAPK1 P28482 2/20 0.67
CYP2D6 P10635 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylparaben SCHEMBL28368 1.00 CA12 (1.00) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL29810737 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL29374744 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL29358972 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL31347872 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL23497074 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL476012 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL31655760 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL475792 0.98 CA12 (0.96) CA12CA1CA2CA7CA9
Ethylparaben SCHEMBL29290346 0.98 CA12 (0.96) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240285646-A1 METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE NEURONASCENT, INC. 2024-08-29 US disclosed
EP-4352058-A1 METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE Neuronascent, Inc. (US) 2024-04-17 EP disclosed
EP-3054936-B1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2023-10-18 EP disclosed
WO-2022261404-A1 METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE NEURONASCENT, INC. (US) 2022-12-15 WO disclosed
US-11274077-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2022-03-15 US disclosed
US-20210323333-A1 IMAGING MEDIUM HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2021-10-21 US disclosed
US-20210039414-A1 IMAGING MEDIUM HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2021-02-11 US disclosed
US-20210023867-A1 IMAGING MEDIUM HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. 2021-01-28 US disclosed
WO-2020117255-A1 IMAGING MEDIA HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) 2020-06-11 WO disclosed
CN-104306764-B A kind of Chinese medicine compound prescription spray for being used to control rhinitis 昆明理工大学 2017-12-22 CN disclosed
CN-106543441-A A kind of polysiloxanes side chain liquid crystalline polymer with smectic phase and preparation method thereof 北京大学 2017-03-29 CN disclosed
CN-104306764-A Traditional Chinese medicine compound spray for treating rhinitis UNIV KUNMING SCIENCE & TECHNOLOGY 2015-01-28 CN disclosed
WO-2007038524-A2 COCRYSTALLIZATION METHODS SSCI, INC. (US) 2007-04-05 WO disclosed
CN-1208603-A Paraffin micro-dispersing composite and hair conditioning prepn. and finishing agent SHISEIDO CO LTD (JP) 1999-02-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274077-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B CA12 3778/4885CA1 4218/4885CA2 1243/4885
US-20240285646-A1 METHODS AND COMPOSITIONS FOR LIPID FORMULATION OF LIPOPHILIC SMALL MOLECULE THERAPIES OF THE HETEROCYCLIC TYPE NLN, SMN1; SMN2, NPC1 CA12 4828/4885CA1 3305/4885CA2 4566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.